CHRS Coherus BioSciences Inc.

16.12
+0.17  (+1%)
Previous Close 15.95
Open 16.5
Price To Book 10.82
Market Cap 1,138,464,764
Shares 70,624,365
Volume 1,475,109
Short Ratio
Av. Daily Volume 1,289,370
Stock charts supplied by TradingView

NewsSee all news

  1. Coherus BioSciences, Inc. (FormDEF 14A) (0001564590-20-015549)

  2. Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., March 20, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today announced that effective March 19, 2020, the compensation committee of the Company's

  3. Coherus BioSciences Management to Present at Barclays Global Healthcare Conference 2020

    REDWOOD CITY, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS), today announced that senior management will present at Barclays Global Healthcare Conference 2020 on

  4. United States Manufactured UDENYCA® (pegfilgrastim-cbqv) Well Positioned to Meet Market Demand

    – US-based supply chain mitigates coronavirus-related disruption risks – – UDENYCA® current inventory of over 300,000 syringes – REDWOOD CITY, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.

  5. Coherus BioSciences Reports Fourth Quarter and Full Year 2019 Financial Results

    – Full Year UDENYCA® Sales of $356.1 Million – – Full Year Cash Flow from Operating Activities of $28.4 million – REDWOOD CITY, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Coherus

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data released January 2016. Endpoints met. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Rheumatoid arthritis
BLA filing due in 2020.
CHS-1420
Psoriasis
Phase 3 trial met endpoint November 2015. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Psoriasis
FDA approval announced November 2, 2018.
CHS-1701
Pegfilgrastim biosimilar
BLA submission withdrawn due to request for additional manufacturing data - February 5, 2020. To be refiled in 2020.
Lucentis Biosimilar
Biosimilar

Latest News

  1. Coherus BioSciences, Inc. (FormDEF 14A) (0001564590-20-015549)

  2. Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., March 20, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today announced that effective March 19, 2020, the compensation committee of the Company's

  3. Coherus BioSciences Management to Present at Barclays Global Healthcare Conference 2020

    REDWOOD CITY, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS), today announced that senior management will present at Barclays Global Healthcare Conference 2020 on

  4. United States Manufactured UDENYCA® (pegfilgrastim-cbqv) Well Positioned to Meet Market Demand

    – US-based supply chain mitigates coronavirus-related disruption risks – – UDENYCA® current inventory of over 300,000 syringes – REDWOOD CITY, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.

  5. Coherus BioSciences Reports Fourth Quarter and Full Year 2019 Financial Results

    – Full Year UDENYCA® Sales of $356.1 Million – – Full Year Cash Flow from Operating Activities of $28.4 million – REDWOOD CITY, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Coherus

  6. Coherus BioSciences Management to Present at the 40th Annual Cowen Healthcare Conference

    REDWOOD CITY, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS), today announced that senior management will present at the 40th Annual Cowen Healthcare Conference on

  7. Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today announced that effective February 18, 2020, the compensation committee of the

  8. Coherus BioSciences to Report Fourth Quarter and Full Year Financial Results on February 27th

    REDWOOD CITY, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or "the Company", NASDAQ:CHRS), today announced that its fourth quarter and full year 2019 financial results will be

  9. Innovent Out-Licenses Commercial Rights for Avastin® Biosimilar to Coherus BioSciences in the United States and Canada

    SUZHOU, China, Jan. 13, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or the "Company") (HKEX: 01801), a biopharmaceutical company that develops and commercializes high quality medicines for

  10. Coherus Acquires Commercial Rights for Avastin® Biosimilar in the United States

    REDWOOD CITY, Calif., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today announced the Company has entered into a licensing agreement with Innovent Biologics,

  11. Coherus BioSciences Management to Present at the 38th Annual J.P. Morgan Healthcare Conference

    REDWOOD CITY, Calif., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS), today announced that senior management will present at the 38th Annual J.P. Morgan Healthcare Conference on

  12. Coherus BioSciences Management to Present at Two Upcoming Investor Healthcare Conferences

    REDWOOD CITY, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS), today announced that senior management will present at two upcoming investor healthcare conferences.

  13. Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today announced that effective November 7, 2019, the compensation committee of the Company's

  14. Coherus Acquires Commercial Rights for Leading Lucentis Biosimilar in the United States

    REDWOOD CITY, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today announced the Company has acquired exclusive rights from Bioeq IP AG, ("Bioeq") a

  15. Coherus BioSciences Reports Corporate Highlights and Third Quarter 2019 Financial Results

    REDWOOD CITY, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today reviewed corporate highlights and reported financial results for the quarter ended

  16. Bioeq Announces Coherus as Marketing and Distribution Partner for Its Biosimilar to Lucentis® (ranibizumab) in the U.S.

    ZÜRICH, Nov. 6, 2019 /PRNewswire/ -- Bioeq IP AG ("Bioeq") today announced that it signed a license and development agreement with Coherus BioSciences, Inc. ((", Coherus", NASDAQ:CHRS), under which Coherus

  17. Bioeq Announces Coherus as Marketing and Distribution Partner for Its Biosimilar to Lucentis® (ranibizumab) in the U.S.

    ZÜRICH, Nov. 6, 2019 /CNW/ -- Bioeq IP AG ("Bioeq") today announced that it signed a license and development agreement with Coherus BioSciences, Inc. ((", Coherus", NASDAQ:CHRS), under which Coherus will

  18. Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., Oct. 18, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or "the Company", NASDAQ:CHRS), today announced that effective October 17, 2019, the compensation committee of the Company's

  19. Coherus BioSciences to Report Third Quarter Financial Results on November 6th

    REDWOOD CITY, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or "the Company", NASDAQ:CHRS), today announced that its third quarter 2019 financial results will be released after market

  20. Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced that effective September 19, 2019, the compensation committee of the company's board of directors

  21. Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced that effective August 21, 2019, the compensation committee of the company's board of directors granted 13